FAQ

ASP015K

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2015
012320152015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.
Two randomized, double-blind, placebo-controlled studies are reported that had the objective to evaluate the pharmacokinetics… (More)
Is this relevant?
2015
2015
Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor.
1. The human mass balance of (14)C-labelled ASP015K ([(14)C]ASP015K), an orally bioavailable Janus kinase (JAK) inhibitor, was… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to…
BACKGROUND Many immune-mediated disorders, including psoriasis, involve cytokine signalling via Janus kinase (JAK) enzymes… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
In vitro/in vivo investigations to examine the gender differences in the pharmacokinetics of novel oral Janus kinase (JAK) inhibitor ASP015K and sulfate metabolite M2 in rats.
1. Although marked gender differences have been reported for the exposure level of the sulfate metabolite M2 of ASP015K in rats… (More)
Is this relevant?